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Abstract
Representatives from academia, industry, regulatory agencies, and patient groups convened 
in March 2019 with the primary goal of developing agreement on chronic hepatitis B virus 
(HBV) treatment endpoints to guide clinical trials aiming to ‘cure’ HBV. Agreement among 
the conference participants was reached on some key points. ‘Functional’ but not sterilizing 
cure is achievable and should be defined as sustained HBsAg loss in addition to undetectable 
HBV DNA 6 months post-treatment. The primary endpoint of phase 3 trials should be 
functional cure; HBsAg loss in ≥30% of patients was suggested as an acceptable rate of 
response in these trials. Sustained virologic suppression (undetectable serum HBV DNA) 
without HBsAg loss, 6 months after discontinuation of treatment would be an intermediate 
goal. Demonstrated validity in predicting sustained HBsAg loss was considered the most 
appropriate criterion for the approval of new HBV assays to determine efficacy endpoints. 
Clinical trials aimed at HBV functional cure should initially focus on patients with HBeAg-
positive and HBeAg-negative chronic hepatitis, treatment-naïve or virally suppressed on 
nucleos(t)ide analogues.  A hepatitis flare associated with increase in bilirubin or INR should 
prompt temporary or permanent cessation of investigational treatment. New treatments must 
be as safe as existing nucleos(t)ide analogues. The primary endpoint for phase 3 trials for 
hepatitis D virus (HDV) co-infection should be undetectable serum HDV RNA 6 months 
after stopping treatment. On treatment HDV RNA suppression associated with normalization 
of ALT is considered an intermediate goal. Conclusion: For HBV ‘functional cure’, sustained 
HBsAg loss with undetectable HBV DNA after completion of treatment is the primary goal 
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Introduction and nomenclature for ‘cure’
To promote and facilitate the planning and execution of new trials in the field of chronic 
hepatitis B (CHB) with the ambition of developing a ‘cure’, the European Association for the 
Study of the Liver (EASL) and the American Association for the Study of Liver Diseases 
(AASLD) jointly organized an hepatitis B virus (HBV) Treatment Endpoint Conference, a 
follow-up to a similar conference in 2016 (1, 2). Participants, representing patient groups, 
regulatory agencies [US Food and Drug Administration (FDA) and European Medicines 
Agency (EMA)], academia and industry assembled in London on March 8-9th 2019. 
This report summarizes the discussions and opinions of the 2-day meeting with an emphasis 
on endpoints and design of clinical trials aimed at HBV ‘cure’. EASL and AASLD selected 
the meeting organizers and the report represents the view of the participants as reported by 
the authors and reviewed and approved by the speakers and moderators of the conference.
In the context of the emergence of novel therapies, the main aim of the conference was to 
develop an agreement on HBV treatment endpoints to guide the design of clinical trials 
aiming to ‘cure’ chronic HBV infection. 
Throughout the meeting, key questions were posed and the participants voted on and 
discussed the options presented. These questions were further examined during a closed 
session involving 24 experts (including the four authors) representing all the stakeholder 
groups. 
Nomenclature
The most appropriate terminology to describe the goal of chronic HBV treatment was 
contentious. While the term ‘cure’ offers hope for both researchers and patients, a sterilizing 
cure for HBV is beyond reach in the near term and any implication of cure might be 
considered as over-reaching. Other less ambitious terms proposed included remission, 
resolved infection, and sustained virologic response but none was preferred.   
For now, the agreement was to keep the term ‘functional cure’. The majority of participants 
agreed that ‘functional HBV cure’ should be defined as durable hepatitis B surface antigen 
(HBsAg) loss (based on assays with lower limit of detection (LLOD) ~0.05 IU/mL) with or 
without HBsAg seroconversion and undetectable serum HBV DNA after completing a course 
of treatment (Table 1). It is recognized that in this situation covalently closed circular (ccc) 
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and integrated HBV DNA is still present. Thus, HBV reactivation can occur spontaneously or 
upon immunosuppression (3). For the patient community, the loss of HBsAg is an important 
goal because it removes the stigma of HBV infection. 
Endpoint definitions for HBV therapy and surrogates for HBV functional cure
HBsAg loss as a surrogate for HBV functional cure
Surrogate endpoints of HBV functional cure measure biochemical (normalization of alanine 
aminotransferase (ALT)), virological (undetectable HBV DNA, HBsAg loss ± 
seroconversion, hepatitis B e antigen (HBeAg) loss ± seroconversion), and histological 
(improvement in inflammation and/or fibrosis) outcomes. Normalization of ALT is a 
problematic endpoint due to a lack of a standardized definition of normal ALT (1, 2), and the 
presence of other common concurrent liver conditions, such as fatty liver, that confound its 
interpretation (4, 5). The assessment of histological improvement is challenged by the need 
for liver biopsy, a procedure infrequently done in clinical practice and a potential barrier to 
clinical trial enrollment. Sustained suppression of HBV DNA under the lower limit of 
detection with current assays is associated with improved clinical outcomes  (6-10). Of note, 
current HBV DNA assays usually have a LLOD of <10 IU/mL. Importantly, undetectable 
HBV DNA plus loss of HBsAg based on current assays with LLOD ~0.05 IU/mL is 
associated with even better outcomes  (11-14). 
HBsAg loss captures virological and clinical aspects of functional cure, in that it is generally 
associated with both undetectable HBV DNA in serum and improvement in clinical outcomes 
(11-14). HBsAg loss is uncommon in nucleos(t)ide analogue (NA)-treated patients, especially 
in Asian patients and those with HBeAg-negative (vs. HBeAg-positive) active hepatitis B 
(11, 15, 16).  However, when it does occur with current therapies, HBsAg loss is usually 
durable, associated with sustained HBV DNA suppression and with incremental reduction in 
hepatocellular carcinoma (HCC) risk compared to viral suppression without HBsAg loss (79-
81, 83).
HBsAg loss induced by NA therapy appears as durable as that occurring spontaneously or 
with pegylated interferon (PEG-IFN) therapy (11, 17, 18). In a retrospective study of 4080 
patients who lost HBsAg (3563 spontaneous and 475 after NA treatment), >90% of patients 
in both groups remained HBsAg negative on follow-up tests although only 38% of patients 
had detectable hepatitis B surface antibody (anti-HBs) at the time of HBsAg loss (18). 
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NA or PEG-IFN induced HBsAg loss, with rates of anti-HBs acquisition increasing over time 
(11, 17, 18). Clarification of the importance of anti-HBs seroconversion on the durability of 
HBsAg loss will influence the definition of HBV functional cure and choice of primary 
efficacy endpoints in clinical trials. Whether duration of consolidation treatment impacts 
durability of HBsAg loss also needs to be determined and will likely depend on the 
mechanism of action of specific HBV drugs. 
Based on current knowledge, the best surrogate of HBV functional cure is HBsAg loss 
confirmed on two occasions at least 6 months apart without requirement for anti-HBs 
seroconversion plus undetectable HBV DNA. This should be the primary endpoint in phase 3 
trials and long-term post treatment follow-up data should be systematically collected to 
document durability of HBsAg loss, rate of anti-HBs seroconversion, and impact on clinical 
outcomes.
Decline in HBsAg levels as predictor for HBsAg loss in early phase trials 
HBsAg loss must be preceded by a decline in HBsAg levels (19). As HBsAg may be 
expressed from both cccDNA and integrated viral DNA sequences, quantitative HBsAg 
levels correlate modestly with intrahepatic cccDNA concentration; newer biomarkers such as 
hepatitis B core related antigen (HBcrAg) and HBV RNA may better reflect cccDNA status 
(20). Early declines in serum HBsAg on treatment are associated with HBsAg loss during or 
after treatment, though with higher negative than positive predictive value (19). Accuracy of 
HBsAg decline in predicting HBsAg loss may be affected by HBeAg status, HBV genotype, 
as well as the type/target of the HBV therapy used (19, 21). 
Therefore, a decline in HBsAg levels in phase 2 clinical trials should currently only be 
considered as an exploratory and not a surrogate endpoint. A decline of HBsAg as a surrogate 
marker in phase 3 trials can only be accepted if it is demonstrated (i.e. in phase 2 trials) to 
reliably predict HBsAg loss. A better predictor for HBsAg loss may be a reduction in HBsAg 
level to a low level, e.g. <100 IU/ml HBsAg (reviewed in (19)). However, more data would 
be required to determine whether a specific threshold level predicts HBsAg loss and whether 
this can be applied to all antiviral and immune-modulatory therapies regardless of mechanism 
of action. 
Reliability of current HBsAg assays to assess HBV functional cure
Current clinical assays for HBsAg have a lower limit of quantification (LLOQ) and lower 
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increased sensitivity (LLOD and LLOQ of ~0.005 IU/mL), but the clinical relevance of low 
levels of HBsAg (0.005-0.05 IU/ml) is unclear (22-24). There are two sources of circulating 
HBsAg, cccDNA and integrated HBV DNA, with  the latter suggested to be a more important 
source of HBsAg in HBeAg-negative patients (25). The efficacy of new antiviral or immune 
modulatory therapies that inhibit or clear cccDNA may not be well-reflected in HBsAg 
measurement if integrated HBV DNA continues to produce HBsAg - unless antiviral immune 
responses are restored and hepatocytes capable of producing HBsAg from cccDNA as well as 
integrated HBV DNA are eliminated. Thus, persistent detection of serum HBsAg may not 
reflect transcription and translation from cccDNA but integrated HBV DNA. The inability of 
current diagnostic tests to differentiate HBsAg derived from integrated HBV DNA vs. 
cccDNA may challenge the use of HBsAg as endpoint for therapy and future studies will 
need to ascertain whether HBsAg derived from integrated versus cccDNA influences 
outcomes.
Serum HBV RNA as a measure of cccDNA and HBV transcription
To quantify cccDNA, a liver biopsy is required. However, specific cccDNA measurement 
remains technically challenging, due to the coexistence of nearly identical HBV DNA 
replicative forms in the liver, and standardized assays are not currently available.  Serum 
biomarkers reflecting the intrahepatic cccDNA concentration and transcription activity are 
desirable and a growing literature suggests that circulating HBV RNA may serve this purpose 
(26, 27). Serum HBV RNA is likely a mixture of intact, pregenomic (pg) and subgenomic, 
spliced, truncated, and polyA-free species (26).  Serum HBV RNA, particularly pgRNA, is 
the most direct measure of cccDNA transcriptional activity and recent data show that serum 
HBV pgRNA levels correlate with intrahepatic pgRNA and cccDNA content (26). 
Serum HBV pgRNA is enriched during NA therapy due to blockage of reverse transcription 
of pgRNA into HBV DNA. It has been shown that detection of serum HBV RNA predicts 
post-treatment viral rebound when NA therapy is stopped (28). Serum HBV RNA 
measurements could also be used to monitor the effectiveness of drugs targeting cccDNA 
transcription and/or pgRNA stability (29, 30). However, more research is needed to further 
characterize the composition of circulating HBV RNA and to assess its role in monitoring 
response to HBV treatment (26). In addition, assays for serum HBV RNA must be 
standardized and validated to ensure that HBV RNA and not a mixture of HBV RNA and 
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HBV RNA vs. spliced RNA vs truncated RNA), and to define the clinical utility of the 
assays. 
Serum HBcrAg as a measure of cccDNA and HBV translation
The HBcrAg assay measures the combined antigenic reactivity resulting from denatured 
HBeAg, HBV core antigen and a truncated incompletely processed precore/core protein 
(p22cr); it has also been advocated for disease monitoring and prognostication of CHB (31-
33). Recent data suggest that HBcrAg exhibits good correlation with intrahepatic cccDNA 
and its transcriptional activity (34). In situations where serum HBV DNA levels have become 
undetectable, the presence of HBcrAg indicates continued transcription from cccDNA. 
HBcrAg has been shown to predict clinical relapse after stopping NA treatment and 
spontaneous or treatment-induced HBeAg seroconversion (33, 35). HBcrAg levels are 
significantly higher in HBeAg-positive patients as current assays also measure HBeAg. There 
is potential clinical utility in using HBcrAg to monitor the response to new HBV treatments 
that target cccDNA, either directly or indirectly (34). The sensitivity of current HBcrAg 
assays appears adequate for monitoring untreated patients with high viremia, but it needs to 
be improved for monitoring response on antiviral treatment (31, 32).
Other markers
Additional viral markers that may help to stratify patients or monitor the success of novel 
therapies are emerging (20) but require further evaluation in larger studies. Quantitative 
hepatitis B core antibody (anti-HBc) might be a useful marker of HBV-induced liver disease 
and might help to discriminate phases of chronic HBV infection and to predict sustained 
response to antivirals as well as risk of HBV reactivation in HBsAg negative patients (36, 
37). New assays that can detect HBsAg bound to anti-HBs in immune complexes may be 
important in confirming HBsAg loss particularly with therapies that specifically target 
HBsAg production (e.g. siRNA-based therapies) (38).
In addition to viral antigens or antibodies and viral DNA or RNA, assessment of host immune 
responses may be useful for the evaluation of HBV patients and efficacy of immune 
modulatory therapies. For example, several studies suggest that soluble inflammatory 
mediators such as serum interferon-inducible protein-10 levels (IP-10 or CXCL-10) are 
associated with HBsAg decline during PEG-IFN or NA therapy (39). However, standardized 
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restoration of HBV-specific T cell function and to evaluate the efficacy of novel immune-
modulatory therapies in clinical trials. 
A full understanding of the biological relevance of these biomarkers is important, as the same 
biomarker may be used to measure target engagement or endpoint of therapy depending on 
the mode of action of the studied drug. 
Current therapies for chronic HBV and HDV infection
The currently approved NAs, tenofovir disoproxil fumarate, tenofovir alafenamide, and 
entecavir, are highly effective and well tolerated. NAs have been shown to reduce 
progression towards cirrhosis, liver failure and HCC (15, 40, 41). Tenofovir disoproxil 
fumarate and entecavir are available as generic drugs at relatively low cost in most parts of 
the world. Tenofovir alafenamide has less adverse effects on bone density and renal function 
compared with tenofovir disoproxil fumarate and similar antiviral efficacy (42). The major 
issue with NAs is that virologic relapse (generally defined as serum HBV DNA >2,000 
IU/mL) as well as clinical relapse, generally defined as serum HBV DNA >2,000 IU/mL and 
ALT >2 times upper limit of normal (>2x ULN), are common when treatment is 
discontinued, even among patients who have had undetectable serum HBV DNA on 
treatment for many years (Figure 1) (43, 44). 
PEG-IFN monotherapy, the other approved therapy for HBV, is finite and may achieve 
higher HBsAg clearance rates, especially in patients with genotypes A and B. However, long-
term HBsAg loss 5 years post treatment is less than 20%. Furthermore, its use is limited due 
to side effects. Thus, stopping rules based on decline in HBsAg levels after 12 or 24 weeks of 
PEG-IFN treatment have been proposed if the chance of sustained virologic control is low 
(45). There is no approved therapy for the treatment of chronic hepatitis D. Off-label use of 
PEG-IFN is the only treatment option for chronic hepatitis D. However, 48- or 96-weeks of 
therapy results in very low rates of sustained off-treatment hepatitis D virus (HDV) RNA 
suppression (46-48). 
Current HBV treatments are well-established, but there remains debate regarding when to 
start and when to stop. In terms of starting treatment, both EASL and AASLD guidelines 
recommend patients with cirrhosis and those with HBeAg positive or HBeAg-negative active 
disease be treated, but there are other groups for whom the benefit is less clear (15, 40, 41). 
Current guidelines do not recommend routine treatment for patients with HBeAg-positive 
chronic infection (also known as “immune tolerant” phase) because these usually young 
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the short-term, spontaneous immune control with HBeAg seroconversion may occur at a later 
point in time, and current treatment rarely results in HBeAg or HBsAg loss (49).  However, 
early treatment would reduce HBV DNA replication with the potential benefits of limiting 
HBV transmission and reducing the future risk of liver complications. Thus, these patients 
would be candidates for treatment if highly effective and finite therapies were available. 
Current guidelines also do not recommend treatment of HBeAg-negative chronic infection 
(inactive carriers), though definitions of inactive carriers are not uniform across different 
guidelines and should be harmonized (15, 40, 41). These patients would be candidates for 
therapy, if finite treatments that were highly effective at clearing HBsAg were available.
In terms of stopping treatment, EASL and AASLD guidelines recommend indefinite NA 
treatment for patients with cirrhosis (15, 40, 41). For HBeAg-positive patients without 
cirrhosis, NAs may be discontinued in those who achieved HBeAg seroconversion and 
completed at least 12 months’ consolidation treatment. For HBeAg-negative patients without 
cirrhosis, EASL guidelines suggest that stopping NA therapy may be considered in selected 
patients without cirrhosis who have undetectable serum HBV DNA for at least 3 years, 
provided close monitoring post-treatment is possible, whereas AASLD guidelines 
recommend indefinite treatment except for those who lose HBsAg (15, 40). Among HBeAg-
negative patients who discontinue NA therapy, viral relapse is almost universal and some 
may experience transient mild hepatitis flares but a proportion will remain in clinical 
remission off treatment and not need retreatment in the short term (43, 50, 51). Small studies 
in Europe have reported rates of HBsAg loss as high as 20-30% within 3 years of stopping 
NAs, whereas studies in Asia have reported lower rates of HBsAg loss (<10%) after similar 
duration of off-treatment follow-up (50-55). Moreover, clinical relapse, hepatitis flares, and 
hepatic decompensation can occur when NAs are stopped (56). Biomarkers that reliably 
predict whether patients will require retreatment or remain in remission are limited, with low 
HBsAg level (variably defined) at the time when NAs are stopped being the best studied 
predictor of sustained clinical remission and HBsAg loss after cessation of therapy (19). 
However, most studies were retrospective with heterogeneous criteria for resuming treatment 
and variable duration of follow-up. More robust data are needed if patients withdrawn from 
NA therapy are to serve as a reference for assessing efficacy of finite courses of HBV 
therapies aimed at functional cure. 
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With improved knowledge of the viral life cycle, the investigation of antivirals with novel 
modes of action is an active and promising area in HBV research (summarized in Table 2). 
HBV entry inhibitors: Knowledge of how HBV enters the hepatocyte has led to the 
development of entry inhibitors (57). These inhibitors can be classified according to their 
modes of action: (1) Neutralizing antibodies target the antigenic loop of HBV S-domain or N-
terminal epitopes in the preS1-domain ; (2) Attachment inhibitors that bind the virus (e.g. 
heparin) or cellular heparan sulphate proteoglycans (e.g. poly-Lysin); (3) Substrates of 
sodium taurocholate co-transporting polypeptide (NTCP) including conjugated bile salts or 
other small molecules;  (4) NTCP inhibitors, such as the myristylated pre-S1 peptide 
Myrcludex-B, Cyclosporin A and derivatives. The latter agents block receptor function at 
non-saturating concentrations with a long half-life at the receptor, and can also block 
transport of bile salts and other NTCP substrates at higher concentrations (57).
Targeting covalently closed circular (ccc) DNA and its transcriptional activity: In cultured 
hepatocytes, several cytokines (IFN-α, lymphotoxin-β receptor agonists, IFN-γ and tumor 
necrosis factor-α) have been shown to modulate pathways leading to the up-regulation of 
APOBEC3A/B deaminases, which in turn induce non-cytolytic, partial degradation of 
cccDNA (58). The discovery of small molecules that are able to inhibit cccDNA formation 
(59) or destabilize the already established cccDNA are being explored. A compound was 
recently reported to decrease the cccDNA pool in hepatocyte culture and in preclinical mouse 
models (60). DNA cleavage enzymes specifically targeting cccDNA, including homing 
endonucleases or meganucleases, zinc-finger nucleases, transcription activator-like effector 
nucleases (TALEN), and CRISPR-associated (cas) nucleases, are being investigated in 
experimental models (61, 62). Delivery issues and avoiding unintended off-target effects, 
including chromosomal recombination, of these gene-editing techniques will need to be 
addressed before they can be investigated in human trials. 
As well as destroying and damaging cccDNA, it may also be possible to block its 
transcriptional activity and shut-down viral protein expression. IFN alfa has been shown to 
decrease cccDNA transcription via epigenetic modifications in preclinical models (63). HBx 
is known to be required for cccDNA transcription and may therefore be an attractive viral 
target to silence not only cccDNA transcription but also several other HBx-dependent virus-
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It was recently shown that pevonedistat, a NEDD8-activating enzyme inhibitor, restored 
Smc5/6 protein levels and suppressed viral transcription and protein production in cultured 
hepatocytes (65). Nitazoxanide, a thiazolide anti-infective agent that has been approved by 
the FDA for protozoan enteritis, was shown to efficiently inhibit the HBx-DDB1 protein 
interaction, restore Smc5 protein levels and suppress viral transcription and viral protein 
production in the same cell culture models (66).
Inhibition of gene expression: Oligonucleotide-based gene expression inhibitors are either 
single-stranded-DNA-like molecules or double-stranded small interfering RNAs (siRNAs).
Single-stranded oligonucleotides (SSO) working through RNase-H-mediated mRNA 
degradation can block viral protein expression and inhibit viral replication. Delivery can be 
achieved, for example, by conjugating the single-stranded oligonucleotides to N-
acetylgalactosamine (GalNAc) moieties. Different single-stranded oligonucleotides are under 
development (67, 68). 
Small interfering RNA (siRNA) can be designed to target any viral transcript and induce its 
degradation by the RISC/Ago2 complex resulting in gene silencing. In a phase 2 study, a 
single dose of ARC-520 in combination with entecavir resulted in a profound and durable 
decrease in serum HBV DNA in both HBeAg-positive and HBeAg-negative patients and 
decrease in HBsAg level in HBeAg-positive but not in HBeAg-negative patients (25). The 
siRNAs were designed to target the 3’ co-termini of all transcripts from cccDNA. The lack of 
effect on HBsAg level in HBeAg-negative patients was postulated to be due to altered viral 
transcript sequences derived from integrated HBV DNA resulting in the truncation of the 
3’end of the transcripts (25). The re-design of the siRNA to target viral transcripts generated 
from integrated as well as cccDNA viral sequences, and the development of new 
formulations based on a GalNac delivery, allowed for subcutaneous administration and 
improved effects on serum HBsAg levels in both HBeAg-positive as well as HBeAg-negative 
patients in Phase 1/2 clinical trials (69). Different siRNA compounds are in preclinical and 
clinical development (Table 2).
Recently, small molecules belonging to dihydroquinolizinone series were shown to induce 
HBs mRNA degradation by targeting a post-transcriptional regulatory element, leading to 
reduction of both viral antigens and viral DNA in vitro (70, 71) and in a pre-clinical mouse 
model (72).
More data are needed to determine whether the decline in HBsAg production induced by 
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alone might be sufficient to restore HBV-specific immunity, or if additional antiviral or 
immune modulatory therapies are needed. 
Nucleocapsid assembly and pregenomic RNA (pgRNA) packaging: The HBV core protein has 
recently emerged as a promising direct antiviral target as it is involved in many aspects of the 
viral lifecycle. Following the elucidation of the 3-dimensional structure of the core protein, 
several classes of non-nucleoside small molecules called core protein assembly (or allosteric) 
modulators (CpAM) have been developed, including phenylpropenamide and 
heteroaryldihydropyrimidine derivatives. These molecules can strengthen protein-protein 
interaction, inhibit pgRNA encapsidation, and block DNA synthesis. There are different 
classes of CpAMs. 
Heteroarylpyrimidine derivatives induce capsids with aberrant morphology and core protein 
aggregates, while phenylpropenamide derivatives or sulfamoylbenzamide derivatives allow 
formation of capsids with normal morphology but devoid of pgRNA (empty capsids). In 
comparison to NAs, CpAMs may have distinct modes of action such as inhibition of 
encapsidation of pgRNA plus inhibition of cccDNA formation, presumably via inhibition of 
the capsid uncoating step (73, 74). The first compound studied in humans was NVR3-778; in 
a dose ranging phase 1b study, serum HBV DNA and HBV RNA decreased but decline in 
HBsAg was mainly observed when combined with PEG- IFN (75). Several CpAMs are in 
preclinical and clinical studies (Table 2).
Targeting HBsAg: Abundant circulating HBsAg may contribute to immune exhaustion. 
Direct inhibition of HBsAg secretion is a promising line of investigation. Nucleic acid 
polymers (NAPs) are broad spectrum antiviral agents that may block the release of HBsAg 
but the exact mode of action still needs to be elucidated. Different nucleic acid polymers 
(REP 2055, REP 2139, REP 2165) used either as monotherapy or with TDF lead-in followed 
by combination of tenofovir disoproxil fumarate, PEG-IFN and nucleic acid polymers 
induced HBsAg clearance and anti-HBs seroconversion in a high proportion of patients with 
HBV infection (76, 77). Similar results were observed in pilot studies of tenofovir disoproxil 
fumarate and PEG-IFN in combination with REP 2139 or REP 2165 in patients with chronic 
HBV and HDV co-infection (78). ALT flares were common during treatment and seemed to 
be correlated with the introduction of PEG-IFN but were not accompanied by signs of liver 
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the durability of response and long-term safety, especially the potential for cytotoxicity 
resulting from intracellular retention of HBsAg.
Immune modulatory therapies
Current direct-acting antiviral therapies are very efficient in controlling viral replication, but 
these treatments require long-term administration and HBsAg loss is rare (16). 
Immunotherapy, either de novo or after NA-suppressed virus replication, may be able to 
maintain virologic suppression or low levels of HBV replication under the control of a 
functional host antiviral response (Table 3). Multiple aspects of the immune responses to 
HBV are defective in chronic infection but the virus remains susceptible when these are 
boosted (79, 80). Inducing robust intrahepatic immune surveillance is likely required for a 
long-term functional cure. 
Interferons: IFN alfa has been used to treat both chronic HBV and chronic HDV infection. 
HBsAg loss rates after a finite course of IFN alfa therapy are higher compared with NA 
therapy. IFN alfa induces expression of IFN sensitive genes encoding intracellular or secreted 
effector proteins with antiviral properties. IFN alfa has also been shown to inhibit pgRNA 
encapsidation, enhance cccDNA degradation, and to exert epigenetic modification of 
cccDNA transcription (81). The immunomodulatory effect of IFN alfa is complex. One 
mechanism is the expansion of natural killer cells exhibiting antiviral activity (82). There is 
still a need to better understand the mechanisms of action of IFN alfa and the basis for the 
higher rates of response in genotype A and B infection. The drawbacks of IFN alfa include 
the side effect profile and the relatively low response rate overall (83). 
Stimulation of pathogen recognition receptors: The initial sensing of infection is mediated by 
these receptors; thus they are a crucial element of the innate immune response. 
Pharmacological activation of the intrahepatic innate immune response with toll-like 
receptors (TLR) 7, 8, or 9 has been studied (80). GS-9620, an oral agonist of TLR7, induced 
a decline in serum HBV DNA and HBsAg levels as well as hepatic HBV DNA in HBV-
infected chimpanzees (84). Similar effects have been observed in woodchucks (85) but not in 
humans (86, 87) despite the induction of host natural killer and HBV-specific T cell 
responses (88). The discrepancies between results in animal models and humans highlight the 
importance of testing new therapies in humans at an early stage in drug development. Other 
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Stimulator of interferon genes (STING) agonists: The stimulator of IFN genes (STING) is the 
adaptor protein of multiple cytoplasmic DNA receptors and can be activated by cyclic 
dinucleotides (89). Therefore, like TLR7/8, stimulator of IFN genes might be activated by 
other small molecules and thus be a potential target for pharmacological activation of the 
innate immune response, as well as priming of an adaptive immune response. Stimulator of 
IFN genes agonists can also be used as adjuvants to therapeutic vaccination. Retinoic-acid-
inducible gene-I (RIG-I) induces both IFN type III and cytokine production and inhibits HBV 
replication by interfering with the interaction of the viral polymerase and the epsilon structure 
of pgRNA (90). SB 9200 (Inarigivir), an oral prodrug of the dinucleotide SB 9000, is thought 
to activate retinoic-acid-inducible-I and nucleotide-binding oligomerization domain-
containing protein 2, resulting in IFN-mediated antiviral immune responses in virus-infected 
cells, and decreased serum woodchuck hepatitis virus DNA and surface antigen levels (91). 
Ongoing clinical trials have shown a mild decrease in serum levels of HBV DNA, HBV RNA 
and HBsAg (92).
Check point modulation: The lack of a T-cell mediated response in chronic HBV is partly due 
to overexpression of co-inhibitory receptors including PD-1, CTLA-4 or TIM-3 (79). 
Immunosuppressive cytokines, such as IL-10, may also impair T cell function and be 
responsible for HBV specific T-cell exhaustion. Blockade of these co-inhibitory mechanisms  
may reverse immune dysfunction in chronic HBV infection as demonstrated ex vivo (93, 94) 
and in animal studies (95) and are being evaluated in human studies in combination with 
therapeutic vaccination (96) .
Therapeutic vaccination: The goal of therapeutic vaccination is to stimulate or boost the host 
immune response to restore immune control resulting in sustained suppression of HBV 
replication and ultimately HBsAg loss. Several therapeutic vaccines have been studied in 
patients with CHB. Although these vaccines have shown some success in animal models, 
results in humans have been disappointing (97). Novel approaches of combination therapy to 
reset a favorable immune environment are being explored to enhance their efficacy. These 
include combinations with check point inhibitors, TLR or retinoic-acid-inducible- I agonists, 
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Engineered HBV-specific T cells: The rarity of HBV-specific immune cells in patients with 
CHB, and their exhausted phenotype and metabolic alterations (98, 99) have driven the 
development of newly engineered HBV-specific T-cells (100). T cells able to recognize 
HBV-infected cells have been constructed using a chimeric antigen receptor made of an anti-
HBs-specific antibody or using canonical HLA-class I restricted HBV-specific T cell 
receptors. Preliminary results using these approaches are encouraging, with specific 
reductions of HBV infected hepatocytes, HBsAg and HBV-DNA in preclinical models (101-
103). Use in patients with HBV related HCC is being investigated (104).
Immune modulatory therapies currently in development are supported by a strong scientific 
rationale but their efficacy in persons with CHB has not yet been demonstrated (Table 3). 
Future clinical trials of immune modulatory therapies will need to explore the role of lead-in 
antiviral therapies not only to suppress HBV replication but also to decrease HBsAg 
production to determine if that will result in a higher likelihood of restoring immune control. 
Combinations of innate immunity boosters and stimulation of adaptive immunity may also be 
required.  
Clinical trials aimed at HBV functional cure
Assessment of safety and indications for stopping trials of new HBV therapies 
Given the well-established safety of NAs, the safety of new HBV therapies will need to be 
comparable and if additional risk is anticipated, well justified for the endpoints achievable. A 
major concern in HBV drug development is occurrence of ALT flares. Three types of flares 
are proposed (Table 5): ‘immune-associated or antiviral flares’ (due to host immune 
responses, accompanied by decline in HBV DNA and viral antigen levels); ‘virus-induced 
flares’ (due to enhanced viral activity, either related to lack of efficacy or drug resistance); 
and ‘drug-induced flares’ (due to undesired effect of drug, such as autoimmunity or drug 
induced liver injury [DILI]). 
The FDA recommendation on DILI management does not apply to patients with underlying 
liver disease who usually have elevated liver enzymes at baseline; therefore, a new approach 
has been proposed that considers both elevations of baseline ALT as well as ALT elevations 
during treatment (105) (Table 6). There is agreement that flares associated with increase in 
bilirubin or INR or hepatic decompensation requires prompt discontinuation of 
investigational therapy. Whether ALT values that trigger halting of treatment can be relaxed, 
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decompensation, increase bilirubin or INR, is unclear. If relaxed, this would only apply to 
patients without advanced fibrosis and in whom HBV DNA levels are decreasing. Flares 
occurring in virally suppressed patients receiving NAs may be more concerning, as these 
likely reflect drug induced liver injury, though they may also reflect immune restoration, 
especially in patients receiving immune modulatory therapies. To differentiate the types of 
flares, it is pertinent to consider their timing, course, associated changes in HBV DNA levels, 
and any concomitant increase in alkaline phosphatase and bilirubin. In some instances, a liver 
biopsy may be necessary to resolve the cause of the flare (Table 6). All patients with flares 
need to be closely monitored to determine whether treatment needs to be halted and if so 
when treatment can be resumed. Flares may also occur after treatment is stopped due to viral 
rebound or immune recovery or delayed liver toxicity. Thus, close monitoring after 
discontinuation of treatment is mandatory.   
Design of phase 2 and 3 trials
The design of phase 2 and phase 3 trials aimed at HBV functional cure requires careful 
consideration of the study populations (Figure 2). Patients in the immune active phase with 
high levels of HBV replication >20,000 IU/ml and hepatic inflammation have the greatest 
immediate need for treatment and also stand to gain the most from an effective therapy. On 
the other hand, NA treatment is safe and efficacious in these patients and the major potential 
advantage of new therapies is to allow a higher percent of patients to have sustained HBV 
DNA suppression or HBsAg loss after completing a finite course of treatment. At the 
opposite end of the spectrum are special populations, e.g. patients with cirrhosis, liver 
transplantation, and children, in whom safety and efficacy of new therapies must be 
established prior to testing in these populations. In patients with cirrhosis, hepatitis flares can 
lead to decompensation and liver-related death/need for liver transplantation; thus, new drug 
therapies, especially those that have a higher risk of inducing flares, need robust safety data 
before being evaluated in this population. Patients with HBeAg-positive infection (immune 
tolerant phase), who have a low risk of liver complications in the short term particularly if 
they are less than 30 years of age, are an important population to consider. A finite therapy 
with a high rate of HBsAg loss may be especially beneficial for this group, as most are 
without significant fibrosis and thus achievement of functional cure is anticipated to prevent 
liver complications in the long term. Effective therapies applied to young patients can also 
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HBV infection is an heterogenous disease and not all therapies may be expected to be 
effective in all patient groups. Thus, the challenge in phase 2 studies is identifying patient 
groups with sufficient homogeneity to allow efficacy to be accurately evaluated. The 
population studied should align with the investigational drug’s mechanism of action. 
Characteristics of potential importance include baseline HBsAg, HBV DNA or ALT levels, 
HBeAg status and duration of NA therapy (for those currently on NA). Many phase 2 studies 
initially target patients who are virally suppressed on NAs; this has the advantage of being an 
easily accessible population (most patients with active disease in care are receiving NAs) that 
is more homogenous and has a lower risk of severe hepatitis flares. Further, given the broad 
use of NAs in clinical practice, clinical designs may evaluate adding new therapies to NA or 
switching from NA to new therapies versus continuation of NA. Alternately, add-on or 
switch therapies using new antivirals may be compared to withdrawal of NAs to determine 
whether higher rates of clinical remission or HBsAg loss can be achieved.  
To improve efficiency, it is desirable to include multiple patient groups in a single trial but 
ensuring that treatment groups are balanced is important because of the possibility of 
heterogeneous responses and sufficient numbers of patients must be included to allow for 
analysis of treatment responses in subgroups. Stratification may be useful, with the factors for 
stratification influenced by the mechanism of action of the drug. For example, HBV genotype 
has been used as stratifying variable in PEG-IFN-based studies. However, due to the modest 
sample size of phase 2 trials, stratification may be limited to only 1 or 2 factors; HBeAg 
might be the most appropriate factor as it ‘captures’ many of the other variables such as 
HBsAg and HBV DNA levels. 
Novel clinical trial strategies should be considered. Adaptive designs allow and even enforce 
continual modifications to key components of trial design while data are being collected. This 
approach can reduce resource use, decrease time to trial completion, limit allocation of 
participants to inferior interventions, and improve the likelihood that trial results will be 
scientifically or clinically relevant (106, 107). However, these innovative trial designs require 
careful planning and early communication with regulatory agencies to ensure all 
requirements for approval are concurrently met. Master protocols are another methodological 
innovation. This is where one overarching protocol is designed to answer multiple questions. 
With a properly designed master protocol, evaluation of more than one or two treatments in 
more than one group of patients can be executed within the same overall trial platform and 
responses compared across treatments or across subgroups receiving the same treatment 
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generally preferred for the endpoint HBsAg loss. However, non-inferiority might also be an 
option, e.g. rates of sustained viral suppression with a finite treatment similar to maintained 
viral suppression during long-term NA treatment.
Design of trials of combination therapies for chronic HBV
Combination therapy will be an essential strategy to improve efficacy and likelihood of HBV 
functional cure (109). Many combinations can be envisioned. A key question is whether two 
or even three antiviral drugs have additive or synergistic effects on HBV replication. For 
example, a direct-acting antiviral might be used to lower viral replication and improve innate 
immune function. A second direct-acting antiviral could then be used to decrease antigen 
load, which might be able to correct immune exhaustion. Addition of a third direct-acting 
antiviral aimed at preventing hepatocytes from new infection events may also be considered. 
Finally, immune-stimulatory agents could be added to upregulate T-cell mediated clearance 
of infected hepatocytes. Using sequential or add-on strategies may allow for the correction of 
immune impairments while minimizing side-effects due to an overwhelming immune 
response. 
Selection of the appropriate patients for combination therapy is crucial. Patients currently not 
on treatment as well as patients who are virally suppressed on NA could be considered. The 
latter might be preferred initially as they already have undetectable HBV DNA and may have 
lower HBsAg levels and thus a higher likelihood of HBsAg loss. 
Discussion on endpoints, trial design, and desired response rates
Primary endpoint for phase 2 clinical trials 
The view of both the EMA and the FDA is that the endpoint in phase 2 clinical trials should 
be tailored to the drug in question and the benefit should outweigh the risk, which would then 
allow subsequent development of the drug. Given that HBsAg loss is the preferred primary 
endpoint for phase 3 clinical trials, the debate regarding the endpoint for phase 2 trials 
centered on HBsAg decline vs. HBsAg loss. While some proposed setting a high bar, i.e. 
requiring HBsAg loss in at least a small percent of participants to minimize the likelihood of 
negative phase 3 trials, others argued for a lower bar in early phase trials, e.g. a >1 or >2 log 
reduction in HBsAg level or a decrease to <100 IU/mL, to minimize the risk of abandoning 
promising drugs that need to be administered for longer duration or in combination with other 
antiviral or immune modulatory therapies to achieve the desired effects. Participants 
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and the goal of new therapies is to achieve what current therapies cannot, i.e. higher rates of 
HBsAg loss with a finite duration of treatment. Thus, phase 2 trials should be looking for an 
early signal of finite treatment efficacy.
Decrease in HBsAg level to <100 IU/mL was suggested as a clinically meaningful endpoint 
because it has been associated with a high probability of subsequent spontaneous HBsAg 
clearance as well as HBsAg clearance after discontinuation of long-term NA therapy (19). 
This endpoint might be easier to achieve in patients with low pre-treatment HBsAg level or 
with drugs that directly target HBsAg production or secretion but may not be appropriate for 
all phase 2 trials. The use of HBsAg decline as a surrogate endpoint will need to be 
sufficiently validated and scientifically justified to ensure progression into phase 3 clinical 
trials.
A particular challenge with designing phase 2 studies is to identify a target population with 
sufficient heterogeneity to be representative of the population with CHB but not so diverse 
that it hinders analysis because of multiple subgroups. 
Primary endpoint and desired response rate for phase 3 clinical trials 
A majority felt that HBsAg loss with or without anti-HBs seroconversion 6 months after 
completion of treatment should be the primary endpoint for phase 3 trials. Suppression of 
serum HBV DNA to undetectable levels would also be required. While over two thirds of the 
participants voted for ‘HBsAg loss in ≥30% of patients after 1 year of therapy’ as the desired 
response rate for phase 3 trials, and judged reasonable by experts, it must be acknowledged 
that this target is arbitrary and not sufficiently nuanced to reflect subcategories of patients for 
which lower target rates of HBsAg loss may be acceptable. A target, although arbitrary, is 
required to guide the first wave of drug development, and this target will be re-assessed based 
on the results of the first phase 2 and phase 3 clinical trials.  It was emphasized that a ‘one-
size fits all’ approach should be avoided as there may be sub-groups of patients who respond 
far better than others and clinical trial design and target response rates should be tailored to 
patient characteristics. In addition, new treatments that can result in sustained off-treatment 
HBV DNA suppression after a short (e.g., <2 years) course of therapy in a high percentage of 
patients should also be considered an improvement over current therapies, even if HBsAg 
loss is not achieved. 
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New assays have been developed to quantify markers of HBV (quantitative HBsAg, HBcrAg, 
HBV RNA, and anti-HBc) as surrogates for hepatic cccDNA, to confirm target engagement 
of new antiviral therapies, and to predict HBsAg loss.  These assays are currently used in 
clinical trials of new antiviral and immune modulatory therapies and need to be standardized 
and validated such that they can be available for clinical use when new drugs are approved. A 
majority felt these assays should have demonstrated validity in predicting HBsAg loss while 
a smaller proportion felt that new HBV markers should have demonstrated utility in guiding 
therapy. 
Prerequisites for testing a new therapy in combination with other (new or existing) therapies
The FDA and EMA requires data on antiviral activity, mechanism of action, safety, and drug-
drug interactions. In situations where a new drug is being combined with a pre-existing drug, 
animal toxicity studies are not required unless there is some non-clinical data indicating that 
there might be overlapping toxicity. However, some drugs in development that do not 
demonstrate the intended antiviral activity in phase 1 or 2 trials may work synergistically in 
combination with other drugs. It was discussed that those drugs may be tested if there are no 
safety concerns and if there is scientific rationale for combination therapies. 
Target patient population for new HBV therapies
A majority of the participants voted for ‘HBeAg-positive or HBeAg-negative CHB virally 
suppressed on NA’ as the target population for initial trials because investigators have easy 
access to these patients and there is less complexity in interpreting ALT flares. The next 
target group for new therapies would be HBeAg-positive or HBeAg-negative immune active 
patients not currently on treatment.  However, some countered that clinical trials should 
target HBeAg-positive infection (immune tolerant) patients first because effective treatments 
are currently available for immune active patients, and also because some new strategies in 
development could have the potential to be particularly effective in this population. One 
advantage of studying immune tolerant patients is the homogeneity of this population; but the 
high HBsAg load might be a bigger challenge for both direct acting antivirals and immune 
modulatory therapies, although the high levels provide a wide dynamic range to quantify 
direct antiviral effects.
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Several compounds with different modes of action are currently in clinical development for 
chronic hepatitis D (Table 4). Surrogate markers and endpoints for HDV treatment are not 
well defined. Recently, a group of experts evaluated the existing evidence and suggested 
possible endpoints that could be used across different clinical trials (110). During this 
endpoint meeting there was no clear agreement on the choice of endpoint for HDV trials; 
specifically, whether finite treatment or maintenance treatment should be the goal and if these 
should vary depending upon the phase of study. Participants preferred undetectable serum 
HDV RNA 6 months after stopping treatment as the endpoint for finite treatment, whereas for 
maintenance treatment, a 2-log reduction in HDV RNA might suffice. Importantly, HDV 
RNA assays need to be standardized according to WHO standard, and only standardized 
assays should be used to evaluate treatment in clinical trials. 
Ideally, finite treatment should also result in HBsAg loss and long-term follow up is needed 
to detect any late relapses. Normalization of ALT is also desired. A concern in HDV 
treatment is the possibility of HBV reactivation when HDV is suppressed. To mitigate this 
risk, NA therapy may be considered in patients before they are enrolled in HDV treatment 
trials, especially if cirrhosis is present. 
Conclusions
Agreement was reached on several important aspects of clinical trials aimed at achieving 
HBV ‘cure’. Until there is agreement on a term that is acceptable to all stakeholders including 
patients, the goal of new HBV treatment is ‘functional cure’ defined as HBsAg loss (based on 
current assays with LLOD ~0.05 IU/mL) and undetectable HBV DNA (based on current 
assays). Seroconversion to anti-HBs is desired but not required. The primary endpoint of 
phase 3 trials should be HBsAg loss and HBV DNA undetectable 6 months after completion 
of treatment. HBsAg loss in ≥30% of patients after 1 year of therapy is the desired rate of 
response in these phase 3 trials. An intermediate goal may be sustained HBV DNA 
suppression without HBsAg loss after completing a short course of therapy currently defined 
as “partial functional cure”. Demonstrated validity in predicting HBsAg loss was voted as the 
most appropriate criterion for the approval of diagnostic assays for new HBV markers used to 
determine efficacy endpoints. Safety as monotherapy and antiviral activity should be ideally 
satisfied before drugs are tested in combination in clinical trials. The HBeAg-positive and 
HBeAg-negative immune active patients who are treatment naïve or are virally suppressed on 
NA should be the priority for phase 2/3 trials aimed at HBV functional cure. Some experts 
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priority groups. HBsAg loss is also the ideal primary endpoint for phase 3 clinical trials of 
new finite HDV treatments. Undetectable serum HDV RNA 6 months after stopping 
treatment is an alternative endpoint. Different endpoints can be used for maintenance 
therapies (e.g. on treatment HDV RNA suppression). 
Given the safety of NAs, new HBV therapies will need to have comparable safety or have 
achievable endpoints that make additional risk justifiable. ALT flares occurring during 
treatment administration associated with an increase in direct bilirubin (>1.0 mg/dL or >20 
umol/L) or INR (>1.5) should prompt temporary or permanent cessation of treatment for all 
patients regardless of ALT level. In addition, it will also be important to investigate patient 
preferences and patient reported outcomes (PROs) in both phase 2 and phase 3 clinical trials.
Designing phase 2 studies is a challenge, particularly with respect to the patient population 
(sufficient heterogeneity to be informative but yet not too heterogenous as to cloud 
interpretation of efficacy), choice of intermediate endpoints to support advancing to phase 3 
studies, and the desired response rate. The design of these studies will be dictated by the 
mode of action of the drugs, the clinical data that exists and the study population.
The agreement gained from this meeting will be instrumental in planning and designing the 
trials that will provide new treatment options for chronic HBV infection that will be finite, 
increase the rate of HBsAg loss or sustained suppression of HBV or HDV replication 
compared to existing therapies, and preserve excellent safety profiles.
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Figures and Tables
Figure 1. Typical courses observed in patients with HBeAg-negative chronic hepatitis B after 
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NB: Rates of HBsAg loss lower in studies of Asian patients. ETV=entecavir, TDF=tenofovir 
disoproxil fumarate. 
Figure 2. Prioritization of patients for enrolment in phase 2 and 3 trials aimed at HBV 
functional cure.
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Table 1. ‘Cures’ in HBV and their definitions (1, 2).






Clinical scenario Never infected Recovery after acute 
HBV
Chronic HBV with 
HBsAg loss
Inactive carrier off 
treatment
HBsAg Negative Negative Negative Positive
Anti-HBs Negative/Positive Positive Positive/negative Negative
HBeAg Negative Negative Negative Negative














Not detected Detected? Detected Detected
Liver disease None None Inactive, fibrosis 
regress over time
Inactive
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Table 2. Summary of new HBV antiviral therapies. *For drugs in preclinical development the list may 
not be complete.
Compound Phase of development Comments / Data
HBV entry inhibitors
NTCP inhibitor 
Myrcludex (Bulevirtide) (Myr 
Pharmaceuticals)
Phase 3 (Hepatitis D)
Phase 1/2 (Hepatitis B)
Strong effect on serum HDV RNA levels, induced ALT normalization under 
monotherapy  (111).
Cyclosporine (CsA) analogues Preclinical Several CsA derivatives inhibited HBV infection with a sub-micromolar IC50 with 
no inhibition of bile acid uptake (112).
Targeting cccDNA 
Destabilizer, Epigenetic regulators, Endonucleases
cccDNA destabilizer
ccc_R08 (Roche)
Preclinical First-in-class orally available HBV cccDNA destabilizer achieved sustained 
HBsAg and HBV DNA suppression in a mouse model (60).
Targeted endonuclease
CRISPR /CAS9
Preclinical Cleavage of cccDNA by Cas9 showed reduction in both cccDNA and other 
parameters of viral gene expression and replication in-vitro (61)
Targeting HBx
CRV431 (ContraVir) Phase 1 Cyclophilin inhibitor that prevents Cyclophilin A-HBx complex formation and 
HBV replication (113).
Nitazoxanide (Romark) Phase 2 First-in-class thiazolide originally developed as antiprotozoal agent. Inhibits 
HBV transcription from cccDNA by targeting the HBx–DDB1 interaction (66). A 
pilot trial showed antiviral efficacy (114).
Inhibition of gene expression / Gene silencing
Antisense Oligonucleotides and Locked Nucleic Acids
GSK3389404 (GlaxoSmith Kline) Phase 2 Methoxyethyl antisense oligonucleotide (ASO) conjugated to 
N-acetylgalactosamine (GalNAc) moieties. Acceptable safety and 
pharmacokinetic profile in phase 1 (68).
LNA SSO2 (Roche) Preclinical Liver-targeted single-stranded oligonucleotide (SSO) therapeutics based on the 
locked nucleic acid (LNA) platform. Rapid and long-lasting reduction of HBsAg 
in a mouse model (67).
RNA interference (RNAi)
ARC-520 (Arrowhead) Development discontinued Decrease in HBsAg level in HBeAg positive but not in HBeAg negative patients 
(25).
JNJ-3989 (Janssen) formerly ARO-HBV-
1001 (Arrowhead)
Phase 1/2 HBsAg reduction in HBeAg positive and HBeAg negative patients. Majority of 
patients achieved HBsAg <100 IU/mL (69).
AB-729 (Arbutus) Preclinical Activity in-vitro and strong HBsAg reduction in mice (115).
ALN-HBV (Alnylam) Preclinical Profound and durable HBsAg silencing in vitro and in vivo (116).




Preclinical Specific blockage of the production of HBV DNA and viral antigens (70, 72, 
117).
Core protein (Capsid) assembly modulators (CpAM)
NVR 3-778 (Novira, Janssen 
Pharmaceutica)
Development discontinued First in-class CpAM showed reduction of HBV DNA and HBV RNA, greater effect 















This article is protected by copyright. All rights reserved
ABI-H0731 (Assembly Bioscience) Phase 2a
RO7049389 (Roche) Phase 2
JNJ-56136379 (Janssen) Phase 2 
AB-506 (Arbutus) Phase 1
ABI-H2158 (Assembly Bioscience) Phase 1
GLS4JHS (Jilin University) Phase 1 / 2
EDP-514 (Enanta) Preclinical
GLP-26 (Emory University) Preclinical
ABI-H3733 (Assembly Bioscience) Preclinical
CpAM show high antiviral efficacy in phase 1 and 2a studies with >2 log decline 
of HBV DNA. HBV RNA decline is stronger with CpAM (ABI-H0731) compared to 
NA therapy (118-124).
HBsAg release inhibitors
Nucleic acid polymers 
(REP compound series) (Replicor)
Phase 2 Small studies with REP compounds (i.v. application) in combination with TDF 
and PEG-IFN in HBV mono-infected and HBV/HDV co-infected patients show 
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Table 3. Summary of new immune modulatory therapies targeting HBV. *For drugs in preclinical 
development the list may not be complete.
Compound Phase of development Comments / Data
Targeting cell intrinsic and Innate Immune responses
RO7020531 (Roche)
TLR 7 agonist
Phase 1 Combination with the CpAM RO7049389 achieved sustained HBV DNA 
suppression and HBsAg loss in a mouse model (125).
Vesatolimod, GS-9620 (Gilead)
TLR 7 agonist
Phase 2 Dose-dependent pharmacodynamic induction of ISG15 and host NK and HBV-
specific T cell responses but no HBsAg reduction in patients (87, 88). Lack of 
effect for cccDNA in-vitro (126).
JNJ-4964 (Janssen)
TLR 7 agonist








Phase 1 Increased IL-1β, IL-6, IL-8 and IFN-γ and reductions in IL-10 levels (129).
Inarigivir soproxil (Spring Bank)
RIG-I agonist
Phase 2 Dual mode of action: RIG-I Agonist and interference with the interaction of the 
viral polymerase and pgRNA.The ACHIEVE trial showed dose dependent 
antiviral response on HBV DNA and HBV RNA (92).
Targeting adaptive immune responses
Check-point Inhibitors
Nivolumab (Opdivo, Bristol-Myers Squibb)
Phase 1 Single dose of Nivolumab (with or without GS4774) showed HBsAg reduction 
>0.5 log in some patients (96).
TG1050/T101 (Transgene/Talsy)
Non-replicative adenovirus serotype 5 
encoding three HBV proteins (Therapeutic 
Vaccine)
Phase 1 Induction of T cell responses in mouse models and reduction of viral 
parameters (130). Dose-related immunogenicity in patients but so far only 
preliminary data on clinical effects (131).
CPmutS (Vaccitech)
Adjuvanted ChAd and MVA vectored 
therapeutic HBV vaccines
Phase 1 Robust T-cell and anti-HBs response in mice (132)
HepTcell (Altimmune)
HBV Peptide therapeutic vaccine with 
TLR9 adjuvant IC31
Phase 1 Human T cell responses against HBV markedly increased over baseline 
compared to placebo but no effect on HBsAg (133).
JNJ-64300535 (Janssen)
Electroporation of DNA vaccine
Phase 1 No clinical data (NCT03463369).
INO-1800 (Inovio)
DNA plasmids encoding HBsAg and 
HBcAg) plus INO-9112 (DNA plasmid 
encoding human interleukin 12)
Phase 1 Activated and expanded CD8+ killer T cells (www.inovio.com)
GS-4774 (Globeimmune, Gilead)
Heat-inactivated, yeast-based, T-cell 
vaccine
development discontinued No significant reductions in serum HBsAg in phase 2 (134)
Genetically engineered T cells / 
Monoclonal or bispecific antibodies
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Table 4. Summary of new HDV antiviral therapies. 
Compound Phase of development Comments / Data
Entry (NTCP) inhibitor 
Myrcludex (Bulevirtide) (Myr 
Pharmaceuticals)
Phase 3 (in progress)  s.c. application
 well tolerated in phase 1/2 clinical studies
 increase in bile acids (no itching)
 monotherapy: decrease in HDV RNA, no effect on 
HBsAg (135)
 combination with PEG-IFN alfa: stronger effect on HDV 
RNA and HBsAg decline (136)
Farnesyltransferase inhibitor Lonafarnib 
(Eiger)
Phase 3 (in progress)  oral application
 higher doses associated with GI side effects (137)
 boosting with ritonavir allows lower doses and reduced 
side effects
 monotherapy: HDV RNA decline, no effect on HBsAg
 combination with PEG-IFN alfa: stronger effect on HDV 
RNA
 post-treatment viral and biochemical flares, which were 
associated with subsequent HDV RNA and ALT response 
(138)
Interferon 
Pegylated Interferon lambda (Eiger)
Phase 2  s.c. application
 fewer adverse events compared with PEG-IFN alfa
 on treatment ALT flares
 > 2log decrease of HDV RNA in 50% (139)
Nucleic acid polymers 
(REP compound series) (Replicor)
Phase 2  i.v. application
 in combination with TDF and PEG-IFN alfa: ALT flares
 strong effect on HDV RNA and HBsAg (78)
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Table 5. Types of ALT flares during treatment. 
“Antiviral flare” “Virus-induced flare” “Drug-induced flare”
Timing of flare Variable depending on 
mechanism of drug
May be early if due to lack of 
efficacy, and variable if due to 
antiviral drug resistance
Any time during treatment
Course of flare Usually self-limiting 
within weeks
Progressive if not recognized 
and remedied
Static or progressive
Association with HBV 
DNA





Normal Normal Normal or elevated
Bilirubin level Usually normal May be elevated Normal or elevated
Liver biopsy Not needed Not needed May be needed for 
diagnosis
Table 6. Proposed combined approach for stopping rules in HBV patients with ALT flares 
during antiviral therapies in a Boston workshop 2012 (105). 
Baseline ALT value Elevation during treatment
1 to less than 2x ULN >5x from baseline and >10x ULN
2 to less than 5x ULN >3x from baseline
Greater or equal to 5x ULN >2x from baseline
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